Item 5. Market for Registrant’s Common Equity
Item
5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Market
Information
Our
common stock and warrants are traded on the Nasdaq Capital Markets under the symbol “STSS” and “STSSW,” respectively.
Our common stock and warrants commenced trading on April 14, 2022. The following tables sets forth the closing high and low price of
the Company’ common stock and warrants, respectively, for the periods indicated as reported on the Nasdaq Capital Markets Exchange.
Common
Stock Closing Prices
2022
High
Low
Second Quarter
$ 2.43
$ 0.83
Third Quarter
$ 1.44
$ 0.95
Fourth Quarter
$ 1.37
$ 1.02
Warrants Closing Prices
2022
High
Low
Second Quarter
$ 0.67
$ 0.25
Third Quarter
$ 0.48
$ 0.15
Fourth Quarter
$ 0.42
$ 0.13
Holders
of Record
As
of March 27, 2023, there were 11,655,936 common shares issued and outstanding and approximately 117 shareholders of record. Because many
of our shares of common stock are held by brokers and other institutions on behalf of stockholders, this number is not indicative of
the total number of stockholders represented by these stockholders of record.
Dividend
Policy
We
have not paid any and have no present intention of paying any dividends on our capital stock. Our current policy is to retain earnings,
if any, for use in our operations and in the development of our business. As a result, we anticipate that only appreciation of the price
of our common stock, if any, will provide a return to investors for at least the foreseeable future.
Use
of Proceeds from the Sale of Registered Securities
On
April 13, 2022, the Company’s initial public offering (“IPO”) was declared effective by the SEC pursuant to which the
Company issued and sold an aggregate of 3,750,000 units, each consisting of one share of common stock and two warrants, to purchase
one share of common stock for each whole warrant, with an initial exercise price of $4.25 per share and a term of five years. In addition,
the Company granted Aegis Capital Corp., as underwriter a 45-day over-allotment option to purchase up to 15% of the number of shares
included in the units sold in the offering, and/or additional warrants equal to 15% of the number of warrants included in the units sold
in the offering, in each case solely to cover over-allotments, which the Aegis Capital Corp. partially exercised with respect to 1,125,000
warrants on April 19, 2022. The IPO generated aggregate gross proceeds of approximately $16 million. After deducting underwriting discounts,
commissions and offering costs incurred by us of approximately $1.7 million the net proceeds from the offering were approximately $14.2
million. Aegis Capital Corp. acted as the underwriter of the offering. No offering costs were paid or are payable, directly, or
indirectly, to our directors or officers, to persons owning 10% or more of any class of our equity securities, or to any of our affiliates.
There has been no material change in the expected use of the net proceeds
from our IPO as described in our final prospectus filed with the SEC on April 15, 2022. Upon receipt, the net proceeds from our IPO were
held in cash and cash equivalents. As of December 31, 2022, we have used approximately $10 million of the net proceeds from the IPO. Pending
such uses, we plan to continue investing the unused proceeds from the IPO in fixed, non-speculative income instruments and money market
funds.
On February 3, 2023,
we completed a securities purchase agreement (“Offering”) with institutional investors and received net proceeds from the
Offering were approximately $3.2 million, net of $600,000 in fees relating to the placement agent and other offering expenses. The Offering
was priced at the market under Nasdaq rules. In connection with the Offering, we issued 2,248,521 units at a purchase price of $1.69
per unit. Each unit consists of one share of common stock and one non-tradable warrant exercisable for one share of common stock at a
price of $1.56. The warrants have a term of five years from the issuance date. (See Notes 16 to the Consolidated Financial Statements)
Recent
Sales of Unregistered Securities
No
unregistered equity securities were issued during the April 19, 2022 through March 27, 2023 except for the 235,000 shares issued
in connection with services provided to the Company.
During
2022, the Company issued 367,500 stock options at exercise prices ranging from $1.08 to $4.25.
During
2021, the Company completed stock subscriptions through a private placement for 487,204 shares of common stock at $7.00 per share. In
addition, the Company issued 71,429 shares to a vendor for engineering and design services provided for equipment and for partial payments
for equipment begin manufactured, 28,571 shares related to an acquisition and 2,857 shares for services.
During
2021, the Company granted 511,764 stock options at an exercise price of $7.00, including 71,248 stock options granted to a vendor relating
to an equipment purchase, 114,285 stock options under an executive employment agreement and 35,714 options relating to an acquisition
agreement.
16
The
offers, sales, and issuances of the above securities were exempt from registration under the Securities Act by virtue of Section 4(a)(2)
of the Securities Act as transactions by an issuer not involving any public offering, or in reliance on Rule 701 promulgated under Section
3(b) of the Securities Act because the transactions were pursuant to compensatory benefit plans or contracts relating to compensation
as provided under Rule 701.
Securities
Authorized for Issuance under Equity Compensation Plans
The
information required by this item with respect to securities authorized for issuance under equity compensation plans is set forth in
Part III, Item 11 of this Annual Report on Form 10-K.
Purchases
of Equity Securities by the Issuer and Affiliated Purchasers
We
did not purchase any of our shares of common stock or other securities during our fiscal year ended December 31, 2022.
Item
6. [Reserved]
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.